Autolus Therapeutics Presents Prelim. Data From Ongoing Phase 1 CARLYSLE Trial In Patients With Severse Refractory Systemic Lupus Erythematosus

Benzinga·12/08/2025 21:07:25

語音播報

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cells
All patients show deep B-cell depletion after infusion, suggesting an immune reset
Nine patients were evaluable for safety, no ICANS or high-grade CRS were observed